COMPARISON OF EFFECTS OF HORMONE REPLACEMENT THERAPY ON SERUM LIPID PROFILE & LIPOPROTEIN(A) IN POSTMENOPAUSAL WOMEN IN A TERTIARY CARE HOSPITAL

SACHI PRASAD BASU; KOUSTUV CHOWDHURY; ARINDAM SUR

doi:10.22159/ajpcr.2024v17i8.51114

Authors

SACHI PRASAD BASU Department of Gynecology, Lady Dufferin Victoria Hospital, Kolkata, West Benga, India.
KOUSTUV CHOWDHURY Department of Pharmacology, R G Kar Medical College and Hospital, Kolkata, West Benga, India. https://orcid.org/0000-0001-5997-5011
ARINDAM SUR Department of Biochemistry, R G Kar Medical College and Hospital, Kolkata, West Benga, India. https://orcid.org/0000-0002-3288-8732

DOI:

https://doi.org/10.22159/ajpcr.2024v17i8.51114

Keywords:

Lipid profile, Lipoprotein(a), Hormone replacement therapy, Estrogen, Progestogen

Abstract

Objective: The study was used to compare the effects of combined estrogen–progestogen therapy and estrogen alone on serum lipid profile and lipoprotein (a).

Methods: A prospective longitudinal study was conducted on the patients attending the Gynecology OPD at the All India Institute of Medical Sciences, New Delhi. Thirty women, who have attained spontaneous or surgical menopause, were selected as cases. All the women with natural menopause received combined estrogen-progestogen therapy (CEE, 0.625 mg and medroxyprogesterone acetate 2.5 mg daily) for 6 months. On the other hand, the women who underwent surgical menopause received only estrogen (CEE 0.625 mg) daily for 6 months lipid profile parameters and lipoprotein (a) were measured using commercially available kits before commencement of treatment and on follow-up (at 3 and 6 months).

Results: There was a 30% decrease in serum lipoprotein (a) level following 6 months of Hormone replacement therapy. This finding confirms with the positive cardioprotective effects of estrogen.

Conclusion: The beneficial effects of estrogen on lipids and lip (a) got partially attenuated when progesterone was added to estrogen.

Downloads

Download data is not yet available.

References

McNeil MA, Merriam SB. Menopause. Ann Intern Med. 2021;174(7):ITC97-112. doi: 10.7326/AITC202107200, PMID 34251902

US Preventive Services Task Force, Mangione CM, Barry MJ, Nicholson WK, Cabana M, Caughey AB, et al. Hormone therapy for the primary prevention of chronic conditions in postmenopausal persons: US preventive services task force rrecommendation sstatement. JAMA. 2022;328(17):1740-6. doi: 10.1001/jama.2022.18625, PMID 36318127

Hall JE. Endocrinology of the Mmenopause. Endocrinol Metab Clin North Am. 2015 Sep;44(3):485-96. doi: 10.1016/j.ecl.2015.05.010, PMID 26316238

Burkard T, Moser M, Rauch M, Jick SS, Meier CR. Utilization pattern of hormone therapy in UK general practice between 1996 and 2015: A descriptive study. Menopause. 2019 Jul;26(7):741-9. doi: 10.1097/ GME.0000000000001300, PMID 30889086

Crandall CJ, Mehta JM, Manson JE. Management of menopausal symptoms: A review. JAMA. 2023;329(5):405-20. doi: 10.1001/ jama.2022.24140, PMID 36749328

El Khoudary SR, Aggarwal B, Beckie TM, Hodis HN, Johnson AE, Langer RD, et al. Menopause transition and cardiovascular disease risk: Implications for timing of early prevention: A scientific statement from the American Heart Association. Circulation. 2020;142(25):e506-32. doi: 10.1161/CIR.0000000000000912, PMID 33251828

Ettinger B, Friedman GD, Bush T, Quesenberry CP Jr. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol. 1996;87:6-12.

Ambikairajah A, Walsh E, Cherbuin N. Lipid Profile differences during menopause: A review with meta-analysis. Menopause. 2019;26(11):1327-33. doi: 10.1097/GME.0000000000001403, PMID 31567869

Baber RJ, Panay N, Fenton A, IMS Writing Group. 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109-50. doi: 10.3109/13697137.2015.1129166, PMID 26872610

Rubenfire M, Brook RD, Rosenson RS. Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events. Am J Med. 2010;123(10):892-8. doi: 10.1016/j. amjmed.2010.03.024, PMID 20920687

Ziaei S, Vakilinia T, Faghihzadeh S. The effects of tibolone on risk factors of cardiovascular disease in menopausal women. Iran J Med Sci. 2010;35(4):281-6.